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Abstract
Background: The Collaborative Assessment and Management of Suicidality (CAMS) is a therapeutic framework that
has been shown to reduce suicidal ideation and overall symptom distress. CAMS has not been previously evaluated
in a standard acute inpatient mental health care setting with only short treatment times for suicidal patients. In this
randomized controlled trial (RCT) we are investigating whether CAMS is more effective than Enhanced-Treatment as
Usual (E-TAU) in reducing suicidal thoughts as primary outcome variable. We are also investigating depressive
symptoms, general symptom relief, and the quality of the therapeutic alliance as secondary outcomes.
Methods/Design: This RCT is designed as a single-center, two-armed, parallel group observer-blinded clinical
effectiveness investigation. We are recruiting and randomizing 60 participants with different diagnoses, who are
admitted as inpatients because of acute suicidal thoughts or behaviors into the Clinic for Psychiatry and
Psychotherapy, Ev. Hospital Bethel in Bielefeld, Germany. The duration of treatment will vary depending on patients’
needs and clinical assessments ranging between 10 and 40 days. Patients are assessed four times, at admission,
discharge, 1 month, and 5 months post-discharge. The primary outcome measure is the Beck Scale for Suicide
Ideation. Other outcome measures are administered as assessment timepoints including severity of psychiatric
symptoms, depression, reasons for living, and therapeutic relationship.
Discussion: This effectiveness study is being conducted on an acute ward in a psychiatric clinic where patients
have multiple problems and diagnoses. Treatment is somewhat limited, and therapists have a large caseloads. The
results of this study can thus be generalizable to a typical inpatient psychiatric hospital settings.
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Background
Approximately 10,000 people die by suicide in Germany
each year, with approximately 28 suicides per day or 1
suicide every 52 min [1]. More than 100,000 people at-
tempt suicide every year in Germany. Over 90% of sui-
cidal cases are associated with mental illness and/or
acute crises and suicidality omnipresent within inpatient
psychiatric settings [2, 3]. Nevertheless, there are sur-
prisingly few empirically evaluated interventions and
guidelines for the actual treatment of suicidal patients
[4, 5], particularly within inpatient psychiatric settings.
Traditional treatment approaches for suicidal risk have
typically targeted underlying mental disorders with lim-
ited proven effectiveness whereas a handful of suicide-
focused clinical treatments have been shown to be ef-
fective for treating suicide risk through randomized con-
trolled trials (RCT’s) [6]. There is extensive RCT
support for Dialectical Behavioral Therapy (DBT) with
borderline patients [7, 8], Brief Cognitive Behavioral
Therapy (BCBT) for military personnel [9], Cognitive
Therapy for Suicide Prevention (CT-SP) with suicide
attempters [10] as well as Mindfulness-Based Cognitive
Behavioral Therapy (MBCT) for chronically depressed
outpatients [11]. Due to time, economic and personnel
limitations, however, these treatments may be rarely
used in routine clinical practice and may only be effect-
ive after a certain prohibitively long duration of therapy.
In the case of acute risk of suicidal risk, however, imme-
diately effective shorter-term interventions are needed.
Leading suicidologists repeatedly have asked, whether
treatment focusing on the mental disorder only is an ef-
fective way to reduce the risk of suicide [12–14]. Some
have proposed that it might be necessary to focus treat-
ment on suicidal risk as an independent syndrome early
in care irrespective of the underlying disorder. Indeed,
the establishment of research criteria for suicidal behav-
iour disorders within the DSM-5 reflects a growing ap-
preciation of this idea. Within their systematic review
and meta-analysis, Meerwijk et al. note that psycho-
therapeutic interventions that directly target suicidal
thoughts and behaviours are more effective in reducing
suicide attempts and suicidal ideation than interventions
that only address these factors indirectly [15]. Conse-
quently, within the contemporary suicide treatment
research, there is an increasing emphasis to develop ef-
fective treatment approaches that quickly and directly
engage the issue of suicidal risk independent of psychi-
atric diagnoses.
Along these lines, the Collaborative Assessment and
Management of Suicidality (CAMS) is a treatment
framework for suicidal patients that specifically focuses
on patient-defined difficulties and challenges that make
consider suicide (referred to as “drivers” within the ap-
proach) [13]. CAMS is thus a semi-structured thera-
peutic framework in which the therapist and the patient
engage in as assessment and intervention process that is
expressly designed to reduce suicidal risk. CAMS em-
phasizes an active collaboration between the patient and
the therapist which is meant to enhance the therapeutic
alliance while increasing the patient’s motivation to live.
To date, CAMS is supported by a range of clinical trial
studies including eight correlational nonrandomized
published trials [13] and four published RCT’s [16–19].
So far, results are promising and suggest that CAMS is
superior to other approaches and leads to a rapid and
sustained reduction of suicidal ideation, overall symptom
distress, and related secondary risk factors such as de-
pression and hopelessness. The impact of CAMS on
self-harm and suicide attempts is promising but limited
thus far [16]. The usefulness of CAMS in longer and pri-
vate inpatient settings has already been previously dem-
onstrated [20, 21]. Ryberg et al. have shown CAMS to be
effective with combined samples of suicidal inpatients
and outpatients [19]. But to further confirm and
generalize such results to a broader population requires
further research. Thus, there is a need for additional ran-
domized controlled trials with comparable treatment
doses of CAMS and TAU within an inpatient context of
a standard psychiatric sample of a public health system
with a short duration of treatment. Moreover, no CAMS
clinical trial studies to date have been carried out in
German-speaking countries.
Method
Aim of the trial
The primary aim of the current study is to investigate
whether CAMS reduces suicidal ideation and suicidal
behaviours more than Enhanced Treatment As Usual
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(E-TAU) within a sample of suicidal inpatients. Secondary
aims are to investigate the effects of CAMS versus E-TAU
on general symptom burden, depression, reasons for
living, and the therapeutic relationship. Furthermore, we
plan to test the influence of various moderating variables
on treatment outcomes; possible moderators will include
diagnostic group (borderline personality disorder in
particular), number of previous suicide attempts, treatment
duration, number of therapeutic sessions, and baseline
levels of psychiatric distress (see [22] for more information
on previous moderators of CAMS).
Trial design
In our pragmatic randomized controlled trial at the
Clinic of Psychiatry and Psychotherapy, Ev. Hospital
Bethel, Germany, CAMS is being compared to E-TAU
within an inpatient crisis setting. The trial is designed as
a single-center, two-armed, parallel-group, observer-
blinded randomized clinical effectiveness trial. Since we
assume that about 50% of the patients we initially exam-
ine do not meet the inclusion criteria, 20% do not con-
sent to participate in the study and 20% discontinue
treatment, we plan to examine 144 patients of the Clinic
who are admitted to the ward due to acute suicidal risk
(thoughts or behaviors) in order to obtain our target
sample size of 60 patients. After screening and random-
izing, the study participants will be followed for about 6
months at four checkpoints t1, t2, t3, t4.
Individuals who are screened positive for the trial
and who gave their written informed consent to take
part in the study are asked to complete a set of ques-
tionnaires (t1) on the admission day or on the work-
day following the admission day. Then, the patient is
randomized and informed about their group member-
ship and the respective interventions begin on the fol-
lowing day. A second follow up assessment (t2) is
carried out between 10 and 40 days later at the day
before discharge. Another follow-up assessment will
be arranged for 4 weeks after discharge (t3). Five
months after the end of treatment, patients will re-
ceive the assessment instruments again by mail (t4).
Refer to Fig. 1 for a schematic overview of the time
flow of the trial and see Appendix 1 for the complete
review of the study questionnaires.
Outcomes of the trial
Primary outcome
Suicidal ideation
Beck scale for suicide ideation (BSS)
The primary outcome in the trial is the change in sui-
cidal ideation severity from baseline measure (t1) to post
assignment (t2) and the follow-up assignments (t3 and
t4). Suicidal Ideation is measured at each assessment by
the German Version of the Beck Scale for Suicide Idea-
tion (BSS [23];). The Beck Scale for Suicidal Ideation is a
self-report instrument for assessing the patient’s severity
of suicidal tendencies. For this purpose, 21 statements
on a rating scale ranging from 0 to 2 are evaluated as
self-assessments and the frequency and seriousness of
previous suicide attempts are reported. BSS questions
are related to the participant’s wish to live, wish to die,
frequency of suicidal ideations, perceived capability to
carry out an attempt, extent of actual preparation, and
similarly oriented queries. The responses of 19 BSS
items are summed up to create an index of suicidal idea-
tion ranging from 0 to 38 with higher scores reflecting
greater ideation. The German scale has been found to be
a valid and reliable measure of suicidal ideation [24].
The English version of the BSS is widely used in suicide
research and has demonstrated predictive validity for
suicide attempts and deaths by suicide [25]. The BSS is
administered at all study time points.
Secondary outcomes
Depression
Beck depression inventory-II (BDI-II)
The BDI-II is a 21-items self-report inventory of depres-
sive symptomatology used to measure depression [26]. It
is one of the most widely used research instruments for
this purpose and has demonstrated good psychometric
properties for use with an inpatient population [27].
Each item is rated on a rating scale from 0 to 3, with
higher scores indicating more severe levels of depressive
symptoms. Previous studies have reported BDI-II means
of 12.75 in a nonclinical student sample [28] and of
21.02 in an inpatient sample [29].
General symptom burden
Symptom Checklist-18-Mini (SCL-18-Mini)
The SCL-18-Mini is a self-report questionnaire that mea-
sures the current extent of the general symptom burden
with 18 items [30]. On a Likert scale from 0 (not at all) to
4 (very much), patients should indicate how much they
have suffered from various complaints in the last 7 days.
Three subscales (somatisation, depression, anxiety) and an
overall index for mental distress can be calculated. There
are excellent coefficients for the internal consistency
(Cronbach’s Alpha); results for convergent, discriminant,
and differential validity are satisfactory to good [31].
Reasons for living
Brief reasons for living inventory (deutsche version) (B-RFL)
The B-RFL is a 12-items form of the Reasons for
Living Inventory which functions as a self-report
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inventory for patients to rate how important each item
would be for living if a suicide is contemplated. Inventory
Items are rated on Likert Scales of 1 (not at all important
as a reason of not killing myself) to 4 (very important as a
reason of not killing myself), with higher scores reflecting
higher reasons to live [32, 33].
The assessment explores the importance of family and
children, religious values, beliefs in the own capabilities,
and the value of living in general. It also assesses the
fears one may have about what others would think as
well as the potential pain involved in a suicidal act which
can be important considerations when someone contem-
plates suicide. The B-RFL has strong psychometric prop-
erties and has been shown to be comparable to the Beck
Depression Inventory (BDI) or the Beck Hopelessness
Scale (BHS) for predicting suicidality [34, 35]. The Brief
Reasons for Living Inventory, which has not yet been
published in German, was translated from English into
German for our study. In order to check and guarantee
the linguistic and content-related correctness, a
translation-back-translation procedure was conducted
with a native speaker.
Therapeutic relationship
German version of the scale to assess the therapeutic
relationship in community mental health care, patient-
version (D-STAR-P)
The quality of the therapeutic relationship will be
assessed by the patient-version of the D-STAR. The D-
STAR-P is a 12-items self-report questionnaire with
three subscales: Positive Collaboration, Positive Clinician
Input, and Nonsuppurative Clinician Input. Loos et al.
(2011) found the psychometric properties to be accept-
able [36]. The feasibility and internal consistency of the
D-STAR-P was good and there is evidence of good con-
vergent validity.
Suicidality
Suicide status form (SSF; CAMS condition only)
Administration of the Suicide Status Form (initial, in-
terim/tracking, and outcome/disposition versions) is an
integral part of the CAMS framework. The SSF is ad-
ministered within a collaborative engagement process
Fig. 1 Overview of the examination procedure
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with the patient, as described in the CAMS treatment
manual [13]. The SSF is a multifaceted instrument,
which is used in the course of the CAMS approach for
risk assessment, treatment planning, tracking of risk, as
well as for documenting all clinical outcomes. The SSF
Core Assessment is made up of five items asking for
subjective ratings (0–5) various suicide-related states:
psychological pain, stress, agitation, hopelessness, and
self-hate (there is also a rating of overall behavioural
risk). This set of variables is administered at the start of
every CAMS session through the course of care and has
strong psychometric validity and reliability with suicidal
inpatients [37]. The first three variables (pain, stress, and
agitation) are based on Shneidman’s cubic model of psy-
chic pain that lies at the heart of his formulation of the
suicidal experiences [38]. The SSF also obtains patient’s
sense of hopelessness (based on the work of Aaron
Beck), and self-hate which is based on Baumeister’s work
conceptualizing suicide as an escape from the pain of
self-loathing [39, 40]. The SSF is further divided into
additional sections to assess the current risk of suicide
and to plan treatment. Responses from the assessment
sections of the SSF are used to inform the CAMS
Stabilization Plan as well as CAMS treatment goals that
focus on patient-defined drivers which make them con-
sider suicide.
Additional measures
In addition to the outcome measures described above,
sociodemographic data (including age, gender, education
and current living situation) are recorded for all examin-
ation times. Furthermore, a short documentation of medi-
cation will take place. This information is gathered in
order to describe the characteristics of the study sample.
Exploratory measures
In order to generate hypotheses for forthcoming studies
and to improve our inpatient treatments, the following
exploratory outcome is assessed:
Components of inpatient treatment
Questionnaire to assess the factors subjectively experienced
as helpful in the context of inpatient crisis intervention
The questionnaire for the evaluation and assessment of
the impact factors of crisis treatment was prepared by us
for this study. Patients describe on 14 items how helpful
they found different aspects of their inpatient treatment,
such as therapeutic sessions, contact with other patients,
pharmacotherapy, the setting of the clinic, the help of the
social worker etc., and in terms of their overall stabilisa-
tion. Inventory items are rated on a Likert Scale from 1
(not helpful at all) to 6 (extremely helpful), with higher
scores indicating more satisfaction with the treatment. In
addition, patients are asked to assign a letter grade for in-
patient treatment and asked to reflect on their health be-
fore and after treatment.
We have intentionally limited the number of research
measures in order not to overtax patients but believe we
will have sufficient data for a meaningful and thorough
research endeavour. Completion of the baseline and the
follow up questionnaires (t1, t2, t3, t4) will take patients
approximately 20–30min each. The test batteries are
handed over by the responsible therapist and are admin-
istered by the research assistant, who is blind to the pa-
tient’s treatment condition.
Study center
The treatments are provided at the Clinic of Psychiatry
and Psychotherapy, Ev. Hospital Bethel in Bielefeld,
Germany. The clinic is responsible for the hospital men-
tal health care of the city of Bielefeld with over 340,000
inhabitants. The study is being carried out on a crisis
ward with 22 treatment beds; approximately 600 in-
patient admissions are performed annually with a mean
duration of stay of 13 days (range 1 to 60).
Study sample
Participant inclusion and exclusion criteria
Patients with acute suicidal thoughts or behaviours are
included who fluently speak and read the German lan-
guage and who are capable to agree to participate in the
study and provide written informed consent. Most pa-
tients are expected to suffer from affective and/or anx-
iety disorders and/or personality disorders. This study is
only treating suicidal inpatients. The consent, legal cap-
acity, and cognitive capacities are clinically evaluated.
When participation is clinically judged to be contraindi-
cated for a particular patient, they are excluded from the
study.
Patients are also excluded who are chronically suicidal
and/or have been treated in an inpatient psychiatric set-
ting for a total of more than 12 weeks within the last 12
months, or who have been admitted more than 6 times
during this period, or who live in an assisted living facil-
ity. In addition, patients with a psychotic disorder during
the last 12 months, an eating disorder with BMI < 16
and/or a current substance dependence are excluded.
Substance abuse or previous substance dependence are
not exclusion criteria. Patients who are currently suffer-
ing from psychotic symptoms as part of an underlying
depressive disorder are also excluded, as are patients
with developmental disabilities, dementia or an organic
condition. Patients are also excluded, who, at the time of
admission, have already planned further long-term in-
patient or day-clinic treatment to continue after crisis
intervention therapy without being discharged in the
meantime, as well as those, who have to be treated on
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our crisis ward for longer than 40 days. However, the
duration of the treatment must be at least 10 days in
order to ensure that patients receive a sufficient extent
of treatment (at least three sessions following the admis-
sion interview). The exclusion criteria are established at
the time of admission (t1) and validated by using the
diagnostic interview any few days later. Patients who are
committed against their will as per civil legal require-
ments (PsychKG of the federal state of North Rhine-
Westphalia or the nationwide valid law of care) do not
take part in the study.
Participant retention
In the context of suicidal crises, spontaneous improve-
ments or treatment discontinuations often occur, e.g.
because the life conditions of the patients have spontan-
eously changed. Nevertheless, we make every reasonable
effort to retain each randomized intent to treat partici-
pant in the study. A telephone appointment between the
end of the treatment and the session that takes place 4
weeks later will serve as means to maintain contact with
the patients and to optimize retention to post-discharge
assessments (t3).
Subject withdrawal criteria and procedures
In the informed consent procedure, participants are in-
formed from their therapists that they can withdraw
their consent from study participation at any time with-
out providing reasons and with no negative conse-
quences. However, clinical staff will ask participants to
share their reasons for withdrawal in order to identify
any adverse impact of study procedures and to identify
any difficulties experienced by subjects during the trial.
Withdrawn participants will have the opportunity to
continue a regular crisis therapy on the ward if this is
clinically indicated.
In addition, participants can be withdrawn from the
trial by the investigators, if an exclusion-criteria is found
after initial inclusion either during the screening-process
or by clinical assessment. For example, a patient who de-
velops psychotic symptoms during the course of treat-
ment may be withdrawn from the study. The participant
is then excluded from the trial and continue with a regu-
lar treatment in the clinic.
Procedures
Recruitment and eligibility screening
The recruitment of the study patients will be carried out
according to consecutive admissions to the ward. Pa-
tients are referred from the hospital, general practi-
tioners, or from somatic wards after suicide attempts;
patients can also self-refer to the clinic setting. When
there are clinical indications during the admission inter-
view for inpatient crisis treatment, and the patient fulfils
the inclusion criteria, they are verbally informed about
the study and are provided with written description of
the study at the same or the following day.
Diagnostic procedures
With a summary of all available information, the current
psychiatric diagnoses are made by at least one psych-
iatrist and one psychologist at the time of the first ad-
mission interview. These diagnoses are double-checked
after a few days of care by an independent research as-
sistant with help of a structured clinical interview. The
research assistant is a Psychologist (B.Sc.) who has been
trained in the diagnostic SCID-interviews. After con-
ducting the clinical diagnostic interview, the research as-
sistant discusses and clinically validates the diagnostic
conclusion with the therapist. All diagnostic data will be
recorded directly on Case Report Forms and are consid-
ered source data.
Diagnosis
Structured clinical interview for DSM-IV Axis I & Axis II
SCID- I & SCID-II The SCID-I is a diagnostic instru-
ment based on diagnostic criteria for Axis I disorders
found in the Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition (DSM-IV-TR [41–43];).
The SCID has been shown to have good reliability with
kappa values ranging from .04 to .84; there is an overall
mean of .61 for all disorders across a large number of
samples. Test-retest reliabilities for disorders in psychi-
atric patients range from .54 to .84 with a mean of .73.
Additionally, the Structured Clinical Interview for DSM-
IV Axis II was used to identify participants with any per-
sonality disorder, because of the higher suicide risk asso-
ciated with personality disorders, which is particularly
true for patients with borderline personality disorder
[44]. The SCID interviews will be conducted after the
baseline assessment within the first days of study
treatment.
Intelligence
Mehrfach-Wortschatz-Intelligenztest (MWT-B)
The Mehrfach-Wortschatz-Intelligenztest [45] is used to
measure the general intelligence level according to a
simple and reliable scheme using verbal material. Pa-
tients are asked in each of the lines to find out if any of
the words presented actually exist and to cross it out. In
each line, according to the multiple-choice principles,
there is one word known in common or scientific lan-
guage among four fictitious new constructions. The total
of 37 items are arranged according to the level of diffi-
culty. The total number of correctly marked lines is
compared with the performance of a representative sam-
ple of German-speaking adults aged 20 to 64 (n = 1952).
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Then standards (IQ, standard value and percentile rank)
can be determined.
See Fig. 2 with all standard protocol items (SPIRIT)
for an overview of the procedures of the clinical trial in-
cluding enrolment, diagnostic and interventions and Ap-
pendix 4 for the SPIRIT checklist.
Interventions
Collaborative Assessment and Management of Suicidality
(CAMS)
In brief terms, CAMS is a suicide-focused psychothera-
peutic approach that targets suicidality as the primary
focus of all clinical assessment and treatment. CAMS is
organized around the assumption that suicidal thoughts
and actions are less a symptom of a mental disorder
than an intrapersonal, logical, and often compelling re-
sponse to psychological stress and suffering. Suicidality
can be a great challenge for the therapeutic relationship
as it often fosters an opposing dynamic (patient versus
therapist) over the struggle to determine whether suicide
is an option or not. CAMS is intended to circumvent
this adversarial dynamic by enabling the patient and
clinician to constructively deal with the patient’s suicidal
tendencies within a non-combative and collaborative
therapeutic dynamic. Within CAMS, the patient and
therapist work together in a focused manner on patient-
defined suicidal “drivers” which are those problems that
cause the patient to consider suicide. The “collaborative”
in CAMS shows itself both content wise and figuratively:
Immediately at the beginning of the CAMS intervention,
the therapist asks the patient to be allowed to sit next to
the patient to fill in the Suicide Status Form (SSF) dur-
ing the survey (“I want to see it through your eyes”,
[13]), so that both can work side by side and together.
CAMS treatment follows a pre-defined format,
using the SSF as a multipurpose assessment and
Fig. 2 Standard protocol items (SPIRIT) for the clinical trial including enrolment, diagnostic assessments and interventions
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treatment planning tool. The continuous monitoring
and work on reducing the impact of patient-defined
suicidal drivers also creates alternative solutions and
perspectives over the course of the sessions ensuring
high-quality suicide-focused treatment that also cre-
ates detailed medical record documentation. A typical
treatment course in our study is characterized by
employing two sessions weekly of 30–60 min duration.
Every session is initiated by filling out the SSF in a
side-by side manner. In the first session, approxi-
mately 20 min are used to fill out the first part of the
SSF as part of the SSF Core Assessment. At the start
of all interim CAMS sessions, approximately 5 mi-
nutes is used to complete the SSF Core Assessment
(as a repeated measure across CAMS-guided care). A
problem-focused treatment plan directly addressing
the patient’s suicidal drivers is jointly developed dur-
ing the first session and routinely evaluated and up-
dated in each following CAMS session. Furthermore,
as part of CAMS-guided care, a stabilization plan is
developed during the first CAMS session and evalu-
ated and improved during every consecutive session
in order to increase the patient’s suicide-related cop-
ing skills. Thorough the course of CAMS-guided care
stabilization and treating suicidal drivers are central
to effective care. Thus, ongoing CAMS care consists
of developing adequate coping skills and helping the
patient identify and cope with their suicidal drivers
more effectively. Within the CAMS framework,
suicidal drivers are further divided in two categories;
direct and indirect drivers. Direct drivers are
thoughts, feelings, or behaviours that increase specific
suicidal risk (e.g., being sexually abused as child or
break up of a marriage). Indirect drivers are factors
that do not produce acute suicidal states but instead
increase the vulnerability and the potential activation
of direct drivers (e.g., drinking, isolation, insomnia).
The CAMS approach does not require any thera-
peutic orientation and does not prescribe precise in-
terventions as to how exactly suicidal drivers should
be treated, which means that the therapist rely on in-
terventions that can treat driver problems (e.g.,
insight-oriented work, vocational counselling, couples
therapy, exposure treatment for trauma).
There are no mandatory homework assignments during
a CAMS course of care. The duration of CAMS-guided
care is dependent on the treatment progress and varies be-
tween patients. The treatment is concluded when the clin-
ician and the patient agree that the acute danger of a
suicidal act is eliminated, adaptive coping skills are devel-
oped while the patient scores him/herself below 3 on sub-
jective suicidal risk rating (on a 5-point scale) and that
they are managing any suicidal thoughts or feelings while
remaining behaviorally stable which may trigger discharge
from the inpatient setting. In the present RCT, cases who
have received between 4 and 9 CAMS sessions including
the initial session will be analysed. See Appendix 2 for the
complete CAMS Material.
Enhanced-treatment as usual (E-TAU)
In addition to the clinic’s standard therapy services,
which CAMS patients also receive, patients in the TAU
condition also receive supportive, behavioural-
therapeutic counselling comparable to the “dose” of
CAMS guided care in the experimental arm of the RCT
(at least three and up to nine 30–60-min sessions during
treatment and one post-operative session). There is no
predefined manual for the TAU treatment. In addition
to establishing a viable therapeutic relationship and
acute relief, diagnostic, psychoeducation and initial
therapeutic steps, the planning of further treatment of
the underlying mental disorders or life problem will be
central. Depending on the current risk situation, the aim
is to promote the patient’s safety, to encourage the pa-
tient to reflect and to build up confidence and motiv-
ation for treatment and the effecting of changes.
Depending on the problem areas described by the pa-
tient, the practitioners independently determine the focal
points and contents of the therapeutic sessions together
with the patients. The therapists are free to choose
methods and strategies to promote self-control and the
use of social support as well as to learn strategies for
emotional stabilisation.
An overview of the various modules of crisis interven-
tion in E-TAU can be found in Fig. 3. To increase ex-
perimental internal validity, TAU in this study was
“enhanced” (i.e., E-TAU). Patients in E-TAU receive as
many treatment sessions as CAMS Patients, approxi-
mately 2 per week, so the amount of treatment is com-
parable in both conditions. Thus, E-TAU is designed to
balance and minimize threats to both the internal and
external validity of the study.
Standard inpatient care (SIC)
SIC contains all non-specific therapy elements that are
identical for both intervention groups. In addition to the
individual psychotherapeutic sessions described above,
there are also occasionally supportive consultations with
the nursing staff. Longer individual nursing contacts due
to crisis situations will be documented in number and
length. A daily morning meeting takes place for all pa-
tients. Depending on the patient’s stability and wishes,
an individual therapy plan is designed so that the patient
can participate in additional offers such as body and
movement therapy, Jacobson relaxation, music therapy,
occupational therapy and offers from clinical social work
and pastoral care. Weekly team meetings serve to
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exchange information on each individual patient be-
tween all the professional groups involved, and weekly
visits by a senior physician also take place. The interven-
tions are embedded in the context of a therapeutic en-
vironment that offers continuous care, supervision, and
plenty of opportunities for spontaneous contact with fel-
low patients.
Choice of comparator
The aim of this trial is to test the effectiveness of CAMS
for suicidal inpatients on an acute crisis ward. For this
purpose, it is necessary to compare CAMS as provided
on the ward with the efficacy of the treatment that
would be available without this module, i.e. a TAU con-
dition. So far, no data exist regarding the effectiveness of
TAU in this understudied population. As described
above, TAU in this study was “enhanced” (i.e., E-TAU),
which means that the treatment dose is comparable in
both conditions, and multiples assessments further im-
prove the patient’s experience, thereby increasing the in-
ternal validity of this RCT.
Medications and treatments permitted/not permitted
during the intervention
In both groups, patients receive medication according to
their diagnosis and current symptoms, based on the clin-
ical judgement of the senior physician (and following
international guidelines). Benzodiazepines and medica-
tion on demand can also be used. All medication and
changes in medication are recorded in both groups. We
expect that medications will be equally represented in
both arms as per randomization. In the follow-up assess-
ments, we will determine which follow-up treatments
the patients has received (e.g., outpatient psychotherapy
or psychiatric treatment as well as any partial care or in-
patient treatment).
Measures taken to minimize/avoid bias, including
randomization and blinding
Randomization
Patients who meet the inclusion criteria and agree to
participate in the study are randomly assigned to one of
the two therapy arms either CAMS (36 subjects) or
TAU (36 subjects). Randomization is performed by an
independent practitioner by throwing the dice immedi-
ately after the patients have agreed to participate in the
study and returned the completed questionnaires (1–3 =
CAMS, 4–6 = E-TAU).
Blinding
Due to the behavioral nature of the intervention, neither
participants nor therapists and therapy interpreters can
be blinded. However, the diagnostic examination is per-
formed by an independent clinician who is blinded for
the study group and we tried to keep the group mem-
bership confidential from the treatment team and from
other patients and study participants, e.g. there was no
documentation about the group membership in the pa-
tient file. Participants are instructed not to reveal any in-
formation related to the group they have been assigned
to or regarding the therapeutic process.
Fig. 3 Diagram showing contents of E-TAU treatment
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Trial monitoring
There are regular appointments with the supervisors
once a month with the main purpose to observe the pro-
gress, the well-being of the patients and to identify prob-
lems in conducting the study and to solve problems
together. Supervisors have access to all documents (e.g.
assessments, audiotapes of therapy sessions, therapy ses-
sion sheets) to check diagnostic accuracy, consistency of
data entry, and adherence to treatment.
Treatment fidelity
The therapists in CAMS and TAU are a licensed psy-
chotherapist and a psychologist (Msc.). The assignment
to the therapist is consecutive, i.e. the clinician who con-
ducted the admission interview will also be responsible
for further treatment. Potential effects of the therapists
will be analysed during the evaluation and using post-
hoc analyses. We trained CAMS therapists with help of
the E-learning training by David Jobes, which both ther-
apists have completed before the start of the study. Add-
itionally, both have worked intensively with the CAMS
manual written by David Jobes. The administration of
the Suicide Status Form (SSF) was practiced by each
therapist with at least 3 patients in a pilot phase prior to
the start of the study. This methodology ensured that
the therapists internalized both the content and process
of CAMS demonstrating sufficient adherence to the
CAMS framework. In the event of difficulties, David
Jobes provides consultation.
Every fourth treatment session of the therapists is su-
pervised. Each therapy session is audiotaped, and the
therapists are rated for adherence according to the
CAMS Rating Scale (CRS) by an external evaluator so
optimal treatment adherence to CAMS is ensured [46].
The supervisors also monitored the E-TAU sessions
using the CRS to ensure and verify that clinicians were
not doing CAMS procedures in these sessions thus en-
suring experimental fidelity. The CRS is an observer rat-
ing scale and consists of three parts and 14 items in
total. Part I covers the treatment philosophy, part 2 the
clinical/ session framework and part 3 the overall rating.
The items were rated on a 6-point scale from 0 = poor
to 6 = excellent. The use of the CRS therefore serves to
confirm the difference in treatment groups with regard
to the fact that the same therapists are treating both
groups. We discussed the problem of the CAMS thera-
pists being also the TAU therapists and the question if
how the therapy is influenced by the knowledge about
the other therapy arm. But in fact, despite the risk of
contamination were mitigated by review of videos and
use of the CRS. Any experimental between-group differ-
ences would provide clear proof of an experimental ef-
fect as the clinicians serve as their own control
(removing a tremendous source of error variance seen in
other RCT’s that use different clinicians in each arm of
the trial).
Treatment feasibility
The feasibility of the measures is assessed on the basis of
dropout rates and the satisfaction with the assigned pro-
cedure is also measured. A therapy dropout is operation-
ally defined if the treatment is terminated before the
conclusion of at least 3 sessions.
Measures taken to avoid attrition bias
In order to prevent an attrition bias, we will endeavour
to examine patients even after a discontinuation of the
study participation (and will conduct our analyses based
on intention to treat methodology). In order to estimate
the extent of a possible bias, the participants who remain
in the study will be compared with those who drop out
prematurely. Because we expect some difficulties in col-
lecting follow-up data (for which patients are expected
to return to the clinic after discharge), a small expense
allowance of 10 Euros for their travel expenses will be
offered to reduce any attrition bias due to systematic
dropouts.
Data handling and quality control
Our clinic is responsible for handling of the data gener-
ated in our institution according to the General Data
Protection Regulation (GDPR). Data storage and transfer
will be conducted exclusively in an encrypted manner.
Three different kinds of data will be produced at the
centers: (1) Personal data including names and contact
information, (2), screening, diagnostic, and therapy
process data (using pseudonyms for participants), and
(3) source data (e.g., audios of assessments and therapy
sessions, therapy session sheets). A separate code list
with a unique identifier for each participant links the
personal data and our use of pseudonyms. The code list
is securely stored at the clinic and will be deleted at the
end of the project duration. We will transfer the dis-
guised and encrypted data to a secure server accessible
only to authorized staff. Checks for completeness will be
conducted to ensure data integrity. Statistical analyses
will be conducted by independent collaborators. Direct
access to trial documents, including source data, is pro-
vided for trial-related monitoring and reviews by the
ethical committee or regulatory authorities if requested
following the guidelines of the GDPR. All individuals
who are authorized to perform the aforementioned re-
views are bound to confidentiality.
Statistics
Power analysis and sample size calculation
An a priori power analysis by using G*Power was carried
out to determine the sample size [47]. On the basis of
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the available literature, we expect an average effect size
(comparison of CAMS versus TAU with regard to the
reduction of suicidal tendencies) of Cohen’s d = 1. Here
we refer to the study by Ellis (2015), which is rather
comparable [21]. The author reports a pre-post effect
size of d = 1.72 for CAMS (measured by the BSS) and of
d = 0.71 for TAU. Although the interaction effect was
not reported we assume it to be about d = 1.
Taking into account a probability of α error = 5% (one-
sided) and a power of 1 - β = 80%, the total sample size
of 48 participants, i.e. 24 per group. For compensating
participants who withdraw their consent we plan 30 sub-
jects per group. Assuming that after the first diagnostic
examination 50% are not eligible for inclusion into the
study due to non-existent inclusion criteria or exclusion
criteria and 20% discontinue treatment in the course of
the study or are excluded due to further inpatient treat-
ment, it is to be expected, that 144 patients have to be
interviewed, of whose 72 patients (36 per group) are ran-
domly assigned to CAMS intervention (36 subjects) and
a TAU (36 subjects), respectively, in order to achieve the
targeted number of N = 2 × 30 in the intent to treat
sample.
Data analyses
Statistical analyses
The analysis of this study will be calculated as a mixed-
effects model with the BSS total symptom score as the
outcome variable. Mixed models are especially suited for
longitudinal studies as they can deal with a correlated
data structure and can analyze all cases and data points,
even if missing values occur in the course of the trial. In
detail, participants will be modeled as a random factor,
while time and intervention (CAMS vs. TAU) as well
their interaction will be modeled as fixed factors. The
hypothesis that CAMS is superior to TAU in the treat-
ment of suicidal patients will be evaluated by the signifi-
cance test of the interaction effect time × intervention.
In case of a significant interaction effect, two planned
general linear hypotheses will be calculated as post-hoc
tests for linear mixed effect models in order to test
between-group differences at t2 and t3. P-values will be
adjusted for multiple comparisons following the Holm
procedure.
We will perform an intention-to-treat analyses, that is,
all trial participants will be analyzed as randomized, even
if they discontinue treatment or are unavailable for one
or both of the follow-up interviews. The between-group
effect size (Cohen’s d) will be calculated at each follow-
up assessment (t2 and t3).
Continuous secondary outcome measures (BDI-II,
SCL-18-Mini, B-RFL, D-STAR-P) are analyzed in the
same way. In absence of a valid cut-off score for clinic-
ally significant change or treatment response of the BSS,
the number of subjects with clinically significant im-
provement as well as worsening based on the reliable
change index (RCI) will be compared between groups
using χ2 –tests or Fisher’s exact tests. For this purpose,
the RCI will be calculated based on the pre-treatment
scores of the study sample. We will use two-tailed tests
for statistical significance with alpha set at P < 0.05.
Effect strength will be determined with Cohen’s d. All
calculations will be performed using SPSS 20.0 computer
software [48].
We also investigate whether there is a correlation be-
tween the number of sessions and the effect of the thera-
peutic treatment using a correlation analysis.
Interim analyses before the completion of the investi-
gations are not intended. Any potential deviations from
the original statistical plan as defined in the study proto-
col will be described in protocol amendments as well as
in the final study report.
Dissemination policy
Dissemination of trial results
The trial results will be disseminated to the scientific
community by publications in international peer-
reviewed journals. The results regarding the primary
outcome of the trial will be published regardless of the
direction and statistical significance of the effect.
In addition, we expect that this trial can inform the
regular health care system (clinics, psychotherapists in
outpatient clinics) about the effect of short-term therapy
for suicidal patients and improve the quality of care. As
there is a lack of methodological sound RCTs for sui-
cidal inpatients we expect that this trial could have a
major impact on the guidelines for the treatment of sui-
cidal patients.
Safety and ethical aspects of the trial
Safety
CAMS previously has been shown to be an effective
treatment model. In a pilot study from 2012, Ellis and
colleagues found that CAMS was successfully imple-
mented and accepted by both patients and clinicians
within the frameworks of an inpatient settings and
Ryberg and colleagues (2019) showed that CAMS was
successfully implemented within a very broad psychiatric
sample with a high symptom load which is probably
comparable to our sample [19, 20]. On this basis we ex-
pect that CAMS most probably will be acceptable and
feasible to the patients and therapists within our clinic.
Psychological stress caused by the examination of the
causes of suicidal tendencies within the treatment is pos-
sible. Negative emotions will occur in all suicidal pa-
tients, this is immanent to the symptoms and treatment
situation. The team at the ward, on which the study is
conducted, is specialized in the treatment of this group
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of patients. In the event of an increase in psychological
stress, patients in emergency situations have nursing
staff on the ward and doctors on duty outside regular
working hours available at all times for supportive
interventions. In an emergency, safety measures can also
be initiated in an inpatient context. Patients would be
excluded if therapists were given the impression that
CAMS or E-TAU treatment is detrimental to the patient.
In the case of suicides in the course of treatment and
study participation that may occur in such a high-risk
group, these are documented by the therapists.
Ethics
The trial has been approved by the Ethical Committee of
the Medical Department of the University of Münster in
Germany on 6 March 2017. Research on a vulnerable
group of patients requires several ethical considerations
to be discussed and addressed, especially when it comes
to suicidal patients, who are excluded from most treat-
ment studies. The major problem in the field of suicide
treatment is that most clinically administered treatments
are not supported by randomized controlled trial investi-
gations (the gold standard for understanding the causal
impact of a treatment).
If we look at the results of previous CAMS clinical trials,
there is no reason to believe that CAMS will have a more
negative effect than TAU, rather the opposite is expected.
The main intention of the study is to evaluate whether
CAMS is more effective than E-TAU. If our hypotheses are
supported, our goal is to contribute to the use of CAMS for
future inpatients within our own and other clinics. It is
important to stress that all suicidal patients will receive
treatment during the study, whether this is CAMS or E-
TAU. Patients in the study receive twice as many therapeutic
consultations as it is assured to other patients on the ward
who do not participate in the study. The increased amount
of therapeutic consultations in both conditions should
motivate patients to participate in the study and ensure that
they receive a sufficient number of treatment sessions even
in the short treatment periods to make a valid comparison
between CAMS and TAU possible and appropriate.
We will not offer a control group who receives no
treatment or postponed treatment. Participation is vol-
untary, and the patients are informed of their possibility
to withdraw from the study at any time with no penalty.
The patients attending the project are not offered any
remuneration, such as payments of gifts for their partici-
pation in the trial. Therefore, we expect little to no other
motives for participation, except general openness, and
hope for an improving care for suicidal inpatients.
Data protection and security
During the trial, sensitive data on the mental health sta-
tus will be collected in the assessments on the Case
Report Forms. A code is used as a surrogate for all case
report forms; the name of the participant will be re-
placed by a code. A separate code list will be maintained
on paper, linking the participant codes with the name
and contact information (for the purpose of contacting
participants for the follow-up assessments). This code
list will be always locked securely and stored separately
from the study records. Furthermore, other source data
(e.g. therapy session sheets, audio cassettes of therapy
sessions), which cannot be identified by codes, are of a
sensitive nature, as they could reveal the identity of the
participant. All participant information will be stored in
locked filing cabinets. Study records which contain
names (e.g., informed consent forms, contact sheets) as
well as data which might allow the identification of the
participant (e.g., audiotapes) will be stored separately
from the Case Report Forms (both physically and
electronically).
Discussion
For our study, we decided to focus on effectiveness of
CAMS. As a result, pragmatic considerations guided our
methodological decisions for the development and im-
plementation of the study. Within effectiveness studies
the “real world” use of an intervention is investigated,
and this helps ascertain whether an intervention can
work within normal practice. The patients seeking our
help in the mental health system often have multiple
problems. By making ongoing suicidality the main inclu-
sion criteria and trying to keep the inclusion criteria very
broad, we expand the generalizability of the trial results.
To enhance the feasibility of this RCT, we use a rather
short test battery.
The trial is a single centre trial and can therefore be
considered as a pilot trial for multicentre trials in the fu-
ture. In order to obtain external validity, we need multi-
centre trials.
In this study we would like to investigate first whether
CAMS is superior to TAU treatment and effective in an
acute inpatient setting. If this is the case, we would like
to investigate the underlying effect mechanisms of
CAMS in further studies.
However, we expect some challenges during the imple-
mentation of the study. The main concerns are associ-
ated with the setting and recruitment. The ward where
the study is carried out is an acute crisis ward with nu-
merous very short treatments and a great deal of fluctu-
ation in the patient population which can create some
degree of disquiet within the milieu and the additional
work for the therapists in the study in everyday life
difficult.
Because the inclusion criteria are very broad, we will
invite as many patients as possible to participate in the
study. There is no preselection. Randomization should
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reduce the risk of a selection bias and various sources of
systematic error. We will also include patients with lon-
ger histories of inpatient psychiatric treatments who
seem to express suicidal thoughts as “crying for help” in
order to receive support, which is sometimes difficult to
distinguish from genuine suicidal tendencies. These pa-
tients are generally regarded as very difficult to treat.
However, we will also include these patients in the study
to see if the treatment supports these patients as well.
The inclusion of these “chronic” patients may, of course,
reduce the effects of the study.
Due to the multiple illnesses of the patients in our
clinic, we expect in particular many patients to have per-
sonality disorders and special needs and expectations in
the treatment, which may cause problems during the
treatment and impact adherence to the manual or to
treatment dropouts.
And finally, it should be noted that the targeted sam-
ple size is quite small, so there must be a large effect to
detect differences between conditions.
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